血液系统恶性肿瘤ICU患者1年死亡率预测模型的开发与验证
本研究为回顾性队列研究,纳入2002至2015年荷兰五家大学医院连续1097例因血液系统恶性肿瘤急性入ICU至少24小时的患者。从22个候选预测因子中构建13变量模型,采用bootstrap减少过拟合,并通过按中心内部-外部交叉验证评估性能。模型C统计量为0.70(95%CI 0.63-0.77),优于APACHE II模型的0.61(95%CI 0.57-0.65);决策曲线分析显示在预测1年死亡率60-100%的临床相关阈值概率范围内有总体净获益。作者认为该模型可能有助于关于继续ICU治疗和临终考虑的共同决策。
要点
- 研究人群为血液系统恶性肿瘤急性入ICU至少24小时的患者,总体1年死亡率为62%(95%CI 59-65)。
- 13变量模型的关键预测因子包括活动性疾病、年龄、既往造血干细胞移植、机械通气、最低血小板计数、急性肾损伤、最高心率和恶性肿瘤类型。
- 模型内部-外部交叉验证C统计量0.70(95%CI 0.63-0.77),优于APACHE II的0.61(95%CI 0.57-0.65)。
- 决策曲线分析显示在预测1年死亡率60-100%的阈值概率范围内有总体净获益。
- 作者认为该模型可能有助于关于继续ICU治疗和临终考虑的共同决策。
适用人群与场景
- 2002至2015年荷兰五家大学医院连续1097例因血液系统恶性肿瘤急性入ICU至少24小时的患者。
研究设计与关键结果
- 研究类型为回顾性队列研究,纳入荷兰五家大学医院2002至2015年连续1097例因血液系统恶性肿瘤急性入ICU至少24小时的患者,无干预。
- 从22个候选预测因子中构建13变量模型,关键预测因子包括活动性疾病、年龄、既往造血干细胞移植、机械通气、最低血小板计数、急性肾损伤、最高心率和恶性肿瘤类型。
- 采用bootstrap程序减少过拟合,通过估计初始模型的乐观度并相应收缩最终模型的回归系数。
- 总体1年死亡率为62%(95%CI 59-65)。
- 13变量模型在按中心内部-外部交叉验证中显示可接受的校准和区分度(C统计量0.70;95%CI 0.63-0.77),优于APACHE II模型(C统计量0.61;95%CI 0.57-0.65)。
- 决策曲线分析显示在预测1年死亡率60-100%的临床相关阈值概率范围内有总体净获益。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为该模型可能有助于关于继续ICU治疗和临终考虑的共同决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop and validate a prediction model for 1-year mortality in patients with a hematologic malignancy acutely admitted to the ICU.
DESIGN: A retrospective cohort study.
SETTING: Five university hospitals in the Netherlands between 2002 and 2015.
PATIENTS: A total of 1097 consecutive patients with a hematologic malignancy were acutely admitted to the ICU for at least 24 h.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We created a 13-variable model from 22 potential predictors. Key predictors included active disease, age, previous hematopoietic stem cell transplantation, mechanical ventilation, lowest platelet count, acute kidney injury, maximum heart rate, and type of malignancy. A bootstrap procedure reduced overfitting and improved the model's generalizability. This involved estimating the optimism in the initial model and shrinking the regression coefficients accordingly in the final model. We assessed performance using internal-external cross-validation by center and compared it with the Acute Physiology and Chronic Health Evaluation II model. Additionally, we evaluated clinical usefulness through decision curve analysis. The overall 1-year mortality rate observed in the study was 62% (95% CI, 59-65). Our 13-variable prediction model demonstrated acceptable calibration and discrimination at internal-external validation across centers (C-statistic 0.70; 95% CI, 0.63-0.77), outperforming the Acute Physiology and Chronic Health Evaluation II model (C-statistic 0.61; 95% CI, 0.57-0.65). Decision curve analysis indicated overall net benefit within a clinically relevant threshold probability range of 60-100% predicted 1-year mortality.
CONCLUSIONS: Our newly developed 13-variable prediction model predicts 1-year mortality in hematologic malignancy patients admitted to the ICU more accurately than the Acute Physiology and Chronic Health Evaluation II model. This model may aid in shared decision-making regarding the continuation of ICU care and end-of-life considerations.
参考来源
- Boldingh JHL, Arbous MS, Biemond BJ, et al. Development and Validation of a Prediction Model for 1-Year Mortality in Patients With a Hematologic Malignancy Admitted to the ICU. Crit Care Explor. 2024. PMID: 38813435. doi:10.1097/CCE.0000000000001093
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。